ISB News

Lee Hood Will Speak at ‘Xconomy Forum: Seattle Biotech Seizes the Momentum’

Dr. Lee Hood will be one of the featured speakers during the next Xconomy Forum on Seattle’s biotech revival. The event takes place on May 6 at Fred Hutchinson Cancer Research Center.

For full details, visit the event page. Promo code: Use XconFriend to get a discount at registration.

Biotech has roared back to life the past couple years, perhaps more than any other U.S. economic sector. Seattle’s biotech community is no different. Last year’s signs of revival include the ascendance of Juno Therapeutics, the burgeoning pipeline of Seattle Genetics, the kickoff of a study that could become a key part of the national precision medicine initiative, and Celgene’s decision to build an R&D center in town.

How should Seattle biotech seize the momentum? Join us at the Fred Hutchinson Cancer Research Center to take part in the discussion.

Confirmed Speakers:

  • Gary Gilliland, President and Director, Fred Hutchinson Cancer Research Center
  • Randy Schatzman, CEO, Alder Biopharmaceuticals
  • Lee Hood, President, The Institute for Systems Biology
  • Chad Robins, President and CEO, Adaptive Biotechnologies
  • Bob Nelsen, Co-founder and Managing Director, ARCH Venture Partners
  • Heather Franklin, CEO, Blaze Bioscience
  • Hans Bishop, CEO, Juno Therapeutics
  • Charlotte Hubbert, Program Investment Officer, The Bill & Melinda Gates Foundation
  • Vikram Jandhyala, Vice President for Innovation, UW Center for Commercialization
  • Matt McIlwain, Managing Director, Madrona Venture Group
  • Mike Gallatin, Senior Advisor, Frazier Healthcare

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.